Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus
{"title":"2003年至2023年儿童流感减毒活疫苗（LAIV）和灭活疫苗（iv）的实际有效性：系统文献综述和网络荟萃分析","authors":"Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus","doi":"10.1080/14760584.2025.2536087","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NMA) estimated absolute VE (aVE) and relative VE (rVE) of LAIV and IIV in children/adolescents from initial LAIV approval in 2003.</p><p><strong>Methods: </strong>Northern Hemisphere studies (2003-2023) with children ≤19 yrs were included. A modified Newcastle-Ottawa Scale assessed risk-of-bias. REMA estimated aVE and three-node NMA (LAIV-IIV-unvaccinated) estimated rVE over three periods: 2003-04 to 2008-09 (pre-2009 A(H1N1) pandemic); 2010-11 to 2016-17 (post-2009 pandemic); 2017-18 to 2022-23 (post-LAIV strain-selection optimization).</p><p><strong>Results: </strong>One hundred and nine studies included. aVE of LAIV and IIV against any influenza was similar (~50%) in each period. Effectiveness of LAIV vs. IIV against influenza types/subtypes was comparable except (1) greater effectiveness with IIV for A(H1N1) in 2010-11 to 2016-17 (rVE -46% [95% CI: -57, -33]); (2) greater effectiveness with LAIV for influenza B in 2017-18 to 2022-23 (rVE 196% [95% CI: 73, 406]). In 2017-18 to 2022-23, effectiveness of LAIV and IIV against A(H1N1) was similar (rVE 10% [95% CI: -35, 87]).</p><p><strong>Conclusions: </strong>LAIV and IIV have demonstrated comparable effectiveness against any influenza in children.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"703-725"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis.\",\"authors\":\"Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus\",\"doi\":\"10.1080/14760584.2025.2536087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NMA) estimated absolute VE (aVE) and relative VE (rVE) of LAIV and IIV in children/adolescents from initial LAIV approval in 2003.</p><p><strong>Methods: </strong>Northern Hemisphere studies (2003-2023) with children ≤19 yrs were included. A modified Newcastle-Ottawa Scale assessed risk-of-bias. REMA estimated aVE and three-node NMA (LAIV-IIV-unvaccinated) estimated rVE over three periods: 2003-04 to 2008-09 (pre-2009 A(H1N1) pandemic); 2010-11 to 2016-17 (post-2009 pandemic); 2017-18 to 2022-23 (post-LAIV strain-selection optimization).</p><p><strong>Results: </strong>One hundred and nine studies included. aVE of LAIV and IIV against any influenza was similar (~50%) in each period. Effectiveness of LAIV vs. IIV against influenza types/subtypes was comparable except (1) greater effectiveness with IIV for A(H1N1) in 2010-11 to 2016-17 (rVE -46% [95% CI: -57, -33]); (2) greater effectiveness with LAIV for influenza B in 2017-18 to 2022-23 (rVE 196% [95% CI: 73, 406]). In 2017-18 to 2022-23, effectiveness of LAIV and IIV against A(H1N1) was similar (rVE 10% [95% CI: -35, 87]).</p><p><strong>Conclusions: </strong>LAIV and IIV have demonstrated comparable effectiveness against any influenza in children.</p>\",\"PeriodicalId\":12326,\"journal\":{\"name\":\"Expert Review of Vaccines\",\"volume\":\" \",\"pages\":\"703-725\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14760584.2025.2536087\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2536087","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis.
Introduction: Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NMA) estimated absolute VE (aVE) and relative VE (rVE) of LAIV and IIV in children/adolescents from initial LAIV approval in 2003.
Methods: Northern Hemisphere studies (2003-2023) with children ≤19 yrs were included. A modified Newcastle-Ottawa Scale assessed risk-of-bias. REMA estimated aVE and three-node NMA (LAIV-IIV-unvaccinated) estimated rVE over three periods: 2003-04 to 2008-09 (pre-2009 A(H1N1) pandemic); 2010-11 to 2016-17 (post-2009 pandemic); 2017-18 to 2022-23 (post-LAIV strain-selection optimization).
Results: One hundred and nine studies included. aVE of LAIV and IIV against any influenza was similar (~50%) in each period. Effectiveness of LAIV vs. IIV against influenza types/subtypes was comparable except (1) greater effectiveness with IIV for A(H1N1) in 2010-11 to 2016-17 (rVE -46% [95% CI: -57, -33]); (2) greater effectiveness with LAIV for influenza B in 2017-18 to 2022-23 (rVE 196% [95% CI: 73, 406]). In 2017-18 to 2022-23, effectiveness of LAIV and IIV against A(H1N1) was similar (rVE 10% [95% CI: -35, 87]).
Conclusions: LAIV and IIV have demonstrated comparable effectiveness against any influenza in children.
期刊介绍：
Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review.
The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
